Pilot trial of sequential dose-dense neoadjuvant chemotherapy plus Herceptin [trastuzumab] in HER2 positive stage II-III breast cancer patients.

Trial Profile

Pilot trial of sequential dose-dense neoadjuvant chemotherapy plus Herceptin [trastuzumab] in HER2 positive stage II-III breast cancer patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2012

At a glance

  • Drugs Cyclophosphamide; Docetaxel; Epirubicin; Trastuzumab
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2012 Additioanl lead trial investigator identified as reported by ClinicalTrials.gov.
    • 18 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 18 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top